| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Biomarin Pharmaceutical Inc.'s insiders have reduced their positions by a net 17,557 shares worth roughly $1.2M.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 214.6K | $11.95M | - | |
| CFO | 123.3K | $6.86M | - | |
| VP | 84.1K | $4.68M | - | |
| VP | 61.0K | $3.40M | - | |
| Dir | 49.4K | $2.75M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2019 | V Bryan Lawlis53 | Director | Sale+OE | 3,750 | $74.47 | $279,262.50 | -13.7% | |
| Jun 17, 2019 | V Bryan Lawlis53 | Director | Sale+OE | 3,750 | $81.08 | $304,050.00 | -13.7% | |
| May 10, 2019 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 10,000 | $82.52 | $825,193.00 | -3.0% | |
| May 9, 2019 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 4,000 | $81.97 | $327,888.40 | -1.2% | |
| May 8, 2019 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 4,000 | $82.16 | $328,624.80 | -1.2% | |
| Apr 26, 2019 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 3,000 | $82.88 | $248,640.40 | -0.9% | |
| Apr 12, 2019 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 4,000 | $89.12 | $356,480.00 | -1.2% | |
| Apr 8, 2019 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 3,000 | $91.87 | $275,597.62 | -0.9% | |
| Apr 5, 2019 | Brian Mueller64 | SVP, Corporate Controller | Sell | 2,953 | $94.00 | $277,582.00 | -17.8% | |
| Apr 5, 2019 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 3,000 | $93.37 | $280,113.60 | -0.9% |